Global Age Related Macular Degeneration Drug Market Growth 2020-2025

November 2020 | 132 pages | ID: G0843972F49EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to this study, over the next five years the Age Related Macular Degeneration Drug market will register a 6.1%% CAGR in terms of revenue, the global market size will reach $ 8507.3 million by 2025, from $ 6708.1 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Age Related Macular Degeneration Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Age Related Macular Degeneration Drug market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Age Related Macular Degeneration Drug, covering the supply chain analysis, impact assessment to the Age Related Macular Degeneration Drug market size growth rate in several scenarios, and the measures to be undertaken by Age Related Macular Degeneration Drug companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.

• Lucentis
• Eylea
• Avastin
• Other

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.

• Hospitals
• Clinics
• Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

• Regeneron Pharmaceuticals
• Bayer HealthCare
• Roche
• Kanghong Pharma
• Novartis

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Age Related Macular Degeneration Drug consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
• To understand the structure of Age Related Macular Degeneration Drug market by identifying its various subsegments.
• Focuses on the key global Age Related Macular Degeneration Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Age Related Macular Degeneration Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Age Related Macular Degeneration Drug submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Age Related Macular Degeneration Drug Consumption 2015-2025
  2.1.2 Age Related Macular Degeneration Drug Consumption CAGR by Region
2.2 Age Related Macular Degeneration Drug Segment by Type
  2.2.1 Lucentis
  2.2.2 Eylea
  2.2.3 Avastin
  2.2.4 Other
2.3 Age Related Macular Degeneration Drug Consumption by Type
  2.3.1 Global Age Related Macular Degeneration Drug Consumption Market Share by Type (2015-2020)
  2.3.2 Global Age Related Macular Degeneration Drug Revenue and Market Share by Type (2015-2020)
  2.3.3 Global Age Related Macular Degeneration Drug Sale Price by Type (2015-2020)
2.4 Age Related Macular Degeneration Drug Segment by Application
  2.4.1 Hospitals
  2.4.2 Clinics
  2.4.3 Other
2.5 Age Related Macular Degeneration Drug Consumption by Application
  2.5.1 Global Age Related Macular Degeneration Drug Consumption Market Share by Type (2015-2020)
  2.5.2 Global Age Related Macular Degeneration Drug Value and Market Share by Type (2015-2020)
  2.5.3 Global Age Related Macular Degeneration Drug Sale Price by Type (2015-2020)

3 GLOBAL AGE RELATED MACULAR DEGENERATION DRUG BY COMPANY

3.1 Global Age Related Macular Degeneration Drug Sales Market Share by Company
  3.1.1 Global Age Related Macular Degeneration Drug Sales by Company (2018-2020)
  3.1.2 Global Age Related Macular Degeneration Drug Sales Market Share by Company (2018-2020)
3.2 Global Age Related Macular Degeneration Drug Revenue Market Share by Company
  3.2.1 Global Age Related Macular Degeneration Drug Revenue by Company (2018-2020)
  3.2.2 Global Age Related Macular Degeneration Drug Revenue Market Share by Company (2018-2020)
3.3 Global Age Related Macular Degeneration Drug Sale Price by Company
3.4 Global Age Related Macular Degeneration Drug Manufacturing Base Distribution, Sales Area, Type by Company
  3.4.1 Global Age Related Macular Degeneration Drug Manufacturing Base Distribution and Sales Area by Company
  3.4.2 Players Age Related Macular Degeneration Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 AGE RELATED MACULAR DEGENERATION DRUG BY REGIONS

4.1 Age Related Macular Degeneration Drug by Regions
4.2 Americas Age Related Macular Degeneration Drug Consumption Growth
4.3 APAC Age Related Macular Degeneration Drug Consumption Growth
4.4 Europe Age Related Macular Degeneration Drug Consumption Growth
4.5 Middle East & Africa Age Related Macular Degeneration Drug Consumption Growth

5 AMERICAS

5.1 Americas Age Related Macular Degeneration Drug Consumption by Countries
  5.1.1 Americas Age Related Macular Degeneration Drug Consumption by Countries (2015-2020)
  5.1.2 Americas Age Related Macular Degeneration Drug Value by Countries (2015-2020)
5.2 Americas Age Related Macular Degeneration Drug Consumption by Type
5.3 Americas Age Related Macular Degeneration Drug Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Age Related Macular Degeneration Drug Consumption by Regions
  6.1.1 APAC Age Related Macular Degeneration Drug Consumption by Regions (2015-2020)
  6.1.2 APAC Age Related Macular Degeneration Drug Value by Regions (2015-2020)
6.2 APAC Age Related Macular Degeneration Drug Consumption by Type
6.3 APAC Age Related Macular Degeneration Drug Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 EUROPE

7.1 Europe Age Related Macular Degeneration Drug by Countries
  7.1.1 Europe Age Related Macular Degeneration Drug Consumption by Countries (2015-2020)
  7.1.2 Europe Age Related Macular Degeneration Drug Value by Countries (2015-2020)
7.2 Europe Age Related Macular Degeneration Drug Consumption by Type
7.3 Europe Age Related Macular Degeneration Drug Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Age Related Macular Degeneration Drug by Countries
  8.1.1 Middle East & Africa Age Related Macular Degeneration Drug Consumption by Countries (2015-2020)
  8.1.2 Middle East & Africa Age Related Macular Degeneration Drug Value by Countries (2015-2020)
8.2 Middle East & Africa Age Related Macular Degeneration Drug Consumption by Type
8.3 Middle East & Africa Age Related Macular Degeneration Drug Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Channels
  10.1.2 Indirect Channels
10.2 Age Related Macular Degeneration Drug Distributors
10.3 Age Related Macular Degeneration Drug Customer

11 GLOBAL AGE RELATED MACULAR DEGENERATION DRUG MARKET FORECAST

11.1 Global Age Related Macular Degeneration Drug Consumption Forecast (2021-2025)
11.2 Global Age Related Macular Degeneration Drug Forecast by Regions
  11.2.1 Global Age Related Macular Degeneration Drug Forecast by Regions (2021-2025)
  11.2.2 Global Age Related Macular Degeneration Drug Value Forecast by Regions (2021-2025)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Age Related Macular Degeneration Drug Forecast by Type
11.8 Global Age Related Macular Degeneration Drug Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 Regeneron Pharmaceuticals
  12.1.1 Company Information
  12.1.2 Age Related Macular Degeneration Drug Product Offered
  12.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2018-2020)
  12.1.4 Main Business Overview
  12.1.5 Regeneron Pharmaceuticals Latest Developments
12.2 Bayer HealthCare
  12.2.1 Company Information
  12.2.2 Age Related Macular Degeneration Drug Product Offered
  12.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2018-2020)
  12.2.4 Main Business Overview
  12.2.5 Bayer HealthCare Latest Developments
12.3 Roche
  12.3.1 Company Information
  12.3.2 Age Related Macular Degeneration Drug Product Offered
  12.3.3 Roche Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2018-2020)
  12.3.4 Main Business Overview
  12.3.5 Roche Latest Developments
12.4 Kanghong Pharma
  12.4.1 Company Information
  12.4.2 Age Related Macular Degeneration Drug Product Offered
  12.4.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2018-2020)
  12.4.4 Main Business Overview
  12.4.5 Kanghong Pharma Latest Developments
12.5 Novartis
  12.5.1 Company Information
  12.5.2 Age Related Macular Degeneration Drug Product Offered
  12.5.3 Novartis Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2018-2020)
  12.5.4 Main Business Overview
  12.5.5 Novartis Latest Developments

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Research Methodology
Table 2. Data Source
Table 3. Age Related Macular Degeneration Drug Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Lucentis
Table 5. Major Players of Eylea
Table 6. Major Players of Avastin
Table 7. Major Players of Other
Table 8. Global Consumption Sales by Type (2015-2020)
Table 9. Global Age Related Macular Degeneration Drug Consumption Market Share by Type (2015-2020)
Table 10. Global Age Related Macular Degeneration Drug Revenue by Type (2015-2020) ($ million)
Table 11. Global Age Related Macular Degeneration Drug Value Market Share by Type (2015-2020) ($ Millions)
Table 12. Global Age Related Macular Degeneration Drug Sale Price by Type (2015-2020)
Table 13. Global Consumption Sales by Application (2015-2020)
Table 14. Global Age Related Macular Degeneration Drug Consumption Market Share by Application (2015-2020)
Table 15. Global Age Related Macular Degeneration Drug Value by Application (2015-2020)
Table 16. Global Age Related Macular Degeneration Drug Value Market Share by Application (2015-2020)
Table 17. Global Age Related Macular Degeneration Drug Sale Price by Application (2015-2020)
Table 18. Global Age Related Macular Degeneration Drug Sales by Company (2017-2019) (K Units)
Table 19. Global Age Related Macular Degeneration Drug Sales Market Share by Company (2017-2019)
Table 20. Global Age Related Macular Degeneration Drug Revenue by Company (2017-2019) ($ Millions)
Table 21. Global Age Related Macular Degeneration Drug Revenue Market Share by Company (2017-2019)
Table 22. Global Age Related Macular Degeneration Drug Sale Price by Company (2017-2019)
Table 23. Global Age Related Macular Degeneration Drug Manufacturing Base Distribution and Sales Area by Manufacturers
Table 24. Players Age Related Macular Degeneration Drug Products Offered
Table 25. Age Related Macular Degeneration Drug Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 26. Global Age Related Macular Degeneration Drug Consumption by Regions 2015-2020 (K Units)
Table 27. Global Age Related Macular Degeneration Drug Consumption Market Share by Regions 2015-2020
Table 28. Global Age Related Macular Degeneration Drug Value by Regions 2015-2020 ($ Millions)
Table 29. Global Age Related Macular Degeneration Drug Value Market Share by Regions 2015-2020
Table 30. Americas Age Related Macular Degeneration Drug Consumption by Countries (2015-2020) (K Units)
Table 31. Americas Age Related Macular Degeneration Drug Consumption Market Share by Countries (2015-2020)
Table 32. Americas Age Related Macular Degeneration Drug Value by Countries (2015-2020) ($ Millions)
Table 33. Americas Age Related Macular Degeneration Drug Value Market Share by Countries (2015-2020)
Table 34. Americas Age Related Macular Degeneration Drug Consumption by Type (2015-2020) (K Units)
Table 35. Americas Age Related Macular Degeneration Drug Consumption Market Share by Type (2015-2020)
Table 36. Americas Age Related Macular Degeneration Drug Consumption by Application (2015-2020) (K Units)
Table 37. Americas Age Related Macular Degeneration Drug Consumption Market Share by Application (2015-2020)
Table 38. APAC Age Related Macular Degeneration Drug Consumption by Countries (2015-2020) (K Units)
Table 39. APAC Age Related Macular Degeneration Drug Consumption Market Share by Countries (2015-2020)
Table 40. APAC Age Related Macular Degeneration Drug Value by Regions (2015-2020) ($ Millions)
Table 41. APAC Age Related Macular Degeneration Drug Value Market Share by Regions (2015-2020)
Table 42. APAC Age Related Macular Degeneration Drug Consumption by Type (2015-2020) (K Units)
Table 43. APAC Age Related Macular Degeneration Drug Consumption Market Share by Type (2015-2020)
Table 44. APAC Age Related Macular Degeneration Drug Consumption by Application (2015-2020) (K Units)
Table 45. APAC Age Related Macular Degeneration Drug Consumption Market Share by Application (2015-2020)
Table 46. Europe Age Related Macular Degeneration Drug Consumption by Countries (2015-2020) (K Units)
Table 47. Europe Age Related Macular Degeneration Drug Consumption Market Share by Countries (2015-2020)
Table 48. Europe Age Related Macular Degeneration Drug Value by Countries (2015-2020) ($ Millions)
Table 49. Europe Age Related Macular Degeneration Drug Value Market Share by Countries (2015-2020)
Table 50. Europe Age Related Macular Degeneration Drug Consumption by Type (2015-2020) (K Units)
Table 51. Europe Age Related Macular Degeneration Drug Consumption Market Share by Type (2015-2020)
Table 52. Europe Age Related Macular Degeneration Drug Consumption by Application (2015-2020) (K Units)
Table 53. Europe Age Related Macular Degeneration Drug Consumption Market Share by Application (2015-2020)
Table 54. Middle East & Africa Age Related Macular Degeneration Drug Consumption by Countries (2015-2020) (K Units)
Table 55. Middle East & Africa Age Related Macular Degeneration Drug Consumption Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Age Related Macular Degeneration Drug Value by Countries (2015-2020) ($ Millions)
Table 57. Middle East & Africa Age Related Macular Degeneration Drug Value Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Age Related Macular Degeneration Drug Consumption by Type (2015-2020) (K Units)
Table 59. Middle East & Africa Age Related Macular Degeneration Drug Consumption Market Share by Type (2015-2020)
Table 60. Middle East & Africa Age Related Macular Degeneration Drug Consumption by Application (2015-2020) (K Units)
Table 61. Middle East & Africa Age Related Macular Degeneration Drug Consumption Market Share by Application (2015-2020)
Table 62. Age Related Macular Degeneration Drug Distributors List
Table 63. Age Related Macular Degeneration Drug Customer List
Table 64. Global Age Related Macular Degeneration Drug Consumption Forecast by Countries (2021-2025) (K Units)
Table 65. Global Age Related Macular Degeneration Drug Consumption Market Forecast by Regions
Table 66. Global Age Related Macular Degeneration Drug Value Forecast by Countries (2021-2025) ($ Millions)
Table 67. Global Age Related Macular Degeneration Drug Value Market Share Forecast by Regions
Table 68. Global Age Related Macular Degeneration Drug Consumption Forecast by Type (2021-2025) (K Units)
Table 69. Global Age Related Macular Degeneration Drug Consumption Market Share Forecast by Type (2021-2025)
Table 70. Global Age Related Macular Degeneration Drug Value Forecast by Type (2021-2025) ($ Millions)
Table 71. Global Age Related Macular Degeneration Drug Value Market Share Forecast by Type (2021-2025)
Table 72. Global Age Related Macular Degeneration Drug Consumption Forecast by Application (2021-2025) (K Units)
Table 73. Global Age Related Macular Degeneration Drug Consumption Market Share Forecast by Application (2021-2025)
Table 74. Global Age Related Macular Degeneration Drug Value Forecast by Application (2021-2025) ($ Millions)
Table 75. Global Age Related Macular Degeneration Drug Value Market Share Forecast by Application (2021-2025)
Table 76. Regeneron Pharmaceuticals Product Offered
Table 77. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 78. Regeneron Pharmaceuticals Main Business
Table 79. Regeneron Pharmaceuticals Latest Developments
Table 80. Regeneron Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Age Related Macular Degeneration Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Bayer HealthCare Product Offered
Table 82. Bayer HealthCare Age Related Macular Degeneration Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 83. Bayer HealthCare Main Business
Table 84. Bayer HealthCare Latest Developments
Table 85. Bayer HealthCare Basic Information, Company Total Revenue (in $ million), Age Related Macular Degeneration Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Roche Product Offered
Table 87. Roche Age Related Macular Degeneration Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 88. Roche Main Business
Table 89. Roche Latest Developments
Table 90. Roche Basic Information, Company Total Revenue (in $ million), Age Related Macular Degeneration Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Kanghong Pharma Product Offered
Table 92. Kanghong Pharma Age Related Macular Degeneration Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 93. Kanghong Pharma Main Business
Table 94. Kanghong Pharma Latest Developments
Table 95. Kanghong Pharma Basic Information, Company Total Revenue (in $ million), Age Related Macular Degeneration Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Novartis Product Offered
Table 97. Novartis Age Related Macular Degeneration Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 98. Novartis Main Business
Table 99. Novartis Latest Developments
Table 100. Novartis Basic Information, Company Total Revenue (in $ million), Age Related Macular Degeneration Drug Manufacturing Base, Sales Area and Its Competitors

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Age Related Macular Degeneration Drug
Figure 2. Age Related Macular Degeneration Drug Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Age Related Macular Degeneration Drug Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Age Related Macular Degeneration Drug Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Lucentis
Figure 7. Product Picture of Eylea
Figure 8. Product Picture of Avastin
Figure 9. Product Picture of Other
Figure 10. Global Age Related Macular Degeneration Drug Consumption Market Share by Type (2015-2020)
Figure 11. Global Age Related Macular Degeneration Drug Value Market Share by Type (2015-2020)
Figure 12. Age Related Macular Degeneration Drug Consumed in Hospitals
Figure 13. Global Age Related Macular Degeneration Drug Market: Hospitals (2015-2020) (K Units)
Figure 14. Global Age Related Macular Degeneration Drug Market: Hospitals (2015-2020) ($ Millions)
Figure 15. Age Related Macular Degeneration Drug Consumed in Clinics
Figure 16. Global Age Related Macular Degeneration Drug Market: Clinics (2015-2020) (K Units)
Figure 17. Global Age Related Macular Degeneration Drug Market: Clinics (2015-2020) ($ Millions)
Figure 18. Age Related Macular Degeneration Drug Consumed in Other
Figure 19. Global Age Related Macular Degeneration Drug Market: Other (2015-2020) (K Units)
Figure 20. Global Age Related Macular Degeneration Drug Market: Other (2015-2020) ($ Millions)
Figure 21. Global Age Related Macular Degeneration Drug Consumption Market Share by Application (2015-2020)
Figure 22. Global Age Related Macular Degeneration Drug Value Market Share by Application (2015-2020)
Figure 23. Global Age Related Macular Degeneration Drug Sales Market Share by Company in 2017
Figure 24. Global Age Related Macular Degeneration Drug Sales Market Share by Company in 2019
Figure 25. Global Age Related Macular Degeneration Drug Revenue Market Share by Company in 2017
Figure 26. Global Age Related Macular Degeneration Drug Revenue Market Share by Company in 2019
Figure 27. Global Age Related Macular Degeneration Drug Sale Price by Company in 2019
Figure 28. Global Age Related Macular Degeneration Drug Consumption Market Share by Regions 2015-2020
Figure 29. Global Age Related Macular Degeneration Drug Value Market Share by Regions 2015-2020
Figure 30. Americas Age Related Macular Degeneration Drug Consumption 2015-2020 (K Units)
Figure 31. Americas Age Related Macular Degeneration Drug Value 2015-2020 ($ Millions)
Figure 32. APAC Age Related Macular Degeneration Drug Consumption 2015-2020 (K Units)
Figure 33. APAC Age Related Macular Degeneration Drug Value 2015-2020 ($ Millions)
Figure 34. Europe Age Related Macular Degeneration Drug Consumption 2015-2020 (K Units)
Figure 35. Europe Age Related Macular Degeneration Drug Value 2015-2020 ($ Millions)
Figure 36. Middle East & Africa Age Related Macular Degeneration Drug Consumption 2015-2020 (K Units)
Figure 37. Middle East & Africa Age Related Macular Degeneration Drug Value 2015-2020 ($ Millions)
Figure 38. Americas Age Related Macular Degeneration Drug Consumption Market Share by Countries in 2019
Figure 39. Americas Age Related Macular Degeneration Drug Value Market Share by Countries in 2019
Figure 40. Americas Age Related Macular Degeneration Drug Consumption Market Share by Type in 2019
Figure 41. Americas Age Related Macular Degeneration Drug Consumption Market Share by Application in 2019
Figure 42. United States Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 43. United States Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 44. Canada Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 45. Canada Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 46. Mexico Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 47. Mexico Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 48. APAC Age Related Macular Degeneration Drug Consumption Market Share by Countries in 2019
Figure 49. APAC Age Related Macular Degeneration Drug Value Market Share by Regions in 2019
Figure 50. APAC Age Related Macular Degeneration Drug Consumption Market Share by Type in 2019
Figure 51. APAC Age Related Macular Degeneration Drug Consumption Market Share by Application in 2019
Figure 52. China Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 53. China Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 54. Japan Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 55. Japan Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 56. Korea Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 57. Korea Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 58. Southeast Asia Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 59. Southeast Asia Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 60. India Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 61. India Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 62. Australia Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 63. Australia Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 64. Europe Age Related Macular Degeneration Drug Consumption Market Share by Countries in 2019
Figure 65. Europe Age Related Macular Degeneration Drug Value Market Share by Countries in 2019
Figure 66. Europe Age Related Macular Degeneration Drug Consumption Market Share by Type in 2019
Figure 67. Europe Age Related Macular Degeneration Drug Consumption Market Share by Application in 2019
Figure 68. Germany Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 69. Germany Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 70. France Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 71. France Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 72. UK Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 73. UK Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 74. Italy Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 75. Italy Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 76. Russia Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 77. Russia Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 78. Middle East & Africa Age Related Macular Degeneration Drug Consumption Market Share by Countries in 2019
Figure 79. Middle East & Africa Age Related Macular Degeneration Drug Value Market Share by Countries in 2019
Figure 80. Middle East & Africa Age Related Macular Degeneration Drug Consumption Market Share by Type in 2019
Figure 81. Middle East & Africa Age Related Macular Degeneration Drug Consumption Market Share by Application in 2019
Figure 82. Egypt Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 83. Egypt Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 84. South Africa Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 85. South Africa Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 86. Israel Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 87. Israel Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 88. Turkey Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 89. Turkey Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 90. GCC Countries Age Related Macular Degeneration Drug Consumption Growth 2015-2020 (K Units)
Figure 91. GCC Countries Age Related Macular Degeneration Drug Value Growth 2015-2020 ($ Millions)
Figure 92. Global Age Related Macular Degeneration Drug Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 93. Global Age Related Macular Degeneration Drug Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 94. Americas Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 95. Americas Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 96. APAC Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 97. APAC Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 98. Europe Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 99. Europe Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 100. Middle East & Africa Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 101. Middle East & Africa Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 102. United States Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 103. United States Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 104. Canada Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 105. Canada Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 106. Mexico Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 107. Mexico Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 108. Brazil Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 109. Brazil Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 110. China Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 111. China Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 112. Japan Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 113. Japan Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 114. Korea Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 115. Korea Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 116. Southeast Asia Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 117. Southeast Asia Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 118. India Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 119. India Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 120. Australia Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 121. Australia Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 122. Germany Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 123. Germany Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 124. France Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 125. France Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 126. UK Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 127. UK Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 128. Italy Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 129. Italy Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 130. Russia Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 131. Russia Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 132. Spain Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 133. Spain Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 134. Egypt Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 135. Egypt Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 136. South Africa Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 137. South Africa Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 138. Israel Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 139. Israel Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 140. Turkey Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 141. Turkey Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 142. GCC Countries Age Related Macular Degeneration Drug Consumption 2021-2025 (K Units)
Figure 143. GCC Countries Age Related Macular Degeneration Drug Value 2021-2025 ($ Millions)
Figure 144. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Market Share (2018-2020)
Figure 145. Bayer HealthCare Age Related Macular Degeneration Drug Market Share (2018-2020)
Figure 146. Roche Age Related Macular Degeneration Drug Market Share (2018-2020)
Figure 147. Kanghong Pharma Age Related Macular Degeneration Drug Market Share (2018-2020)
Figure 148. Novartis Age Related Macular Degeneration Drug Market Share (2018-2020)